Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).

被引：4
|
作者：
Munster, Pamela N.
Hamilton, Erika Paige
Franklin, Catherine
Bhansali, Suraj
Wan, Kitty
Hewes, Becker
Juric, Dejan
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] Novartis Inst Biomed Res, Cambridge, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
    Bardia, Aditya
    Modi, Shanu
    Gregor, Mariana Chavez-Mac
    Kittaneh, Muaiad
    Marino, Alyssa J.
    Matano, Alessandro
    Bhansali, Suraj
    Hewes, Becker
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2-eBC)
    Geyer, Charles
    Bardia, Aditya
    Harbeck, Nadia
    Rimawi, Mothaffar F.
    Hurvitz, Sara A.
    Martin, Miguel
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovskiy, Daniil
    Lopez-Valverde, Vanesa
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer
    Rojas, Kristin E.
    Manasseh, Donna-Marie
    Rojas, Mary
    Mattocks, Andrea
    Portnow, Leah
    Kantharia, Sarah
    Zelenko, Natalie
    Giuliano, Christina
    Borgen, Patrick, I
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 79 - 83
  • [34] Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)
    Skriver, Signe Korsgaard
    Laenkholm, Anne-Vibeke
    Rasmussen, Birgitte Bruun
    Handler, Juergen
    Grundtmann, Bo
    Tvedskov, Tove Filtenborg
    Christiansen, Peer
    Knoop, Ann S.
    Jensen, Maj-Britt
    Ejlertsen, Bent
    ACTA ONCOLOGICA, 2018, 57 (01) : 31 - 37
  • [35] PHASE II RANDOMIZED STUDY OF PRE-OPERATIVE PF-04691502 PLUS LETROZOLE COMPARED WITH LETROZOLE (L) IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER (BC)
    Dowsett, M.
    Koehler, M.
    Millham, R.
    Borzillo, G.
    A'Hern, R.
    Pierce, K.
    Barton, J.
    Giorgetti, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 44 - 44
  • [36] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [37] Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)
    Hamilton, E.
    Vidula, N.
    Ma, C.
    LoRusso, P.
    Bagley, R. G.
    Yu, Z.
    Annett, M.
    Weitzman, A.
    Conlan, M. G.
    Weise, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [39] Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
    Basaran, Gul A.
    Twelves, Chris
    Dieras, Veronique
    Cortes, Javier
    Awada, Ahmad
    CANCER TREATMENT REVIEWS, 2018, 63 : 144 - 155
  • [40] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
12345